Inflammatory Markers in Cancer Immunotherapy

Area of Science:

• Oncology
• Immunology
• Biochemistry

Background:

• Chronic inflammation is a significant risk factor for cancer development.
• Inflammation in the tumor microenvironment influences cancer growth, therapy response, and prognosis.
• Systemic inflammation and specific markers like C-reactive protein and IL-6 correlate with cancer progression.

Purpose of the Study:

• To review the role of cancer-associated inflammation in tumorigenesis and disease progression.
• To discuss the implications of inflammatory markers in malignancies treated with immunotherapy.
• To explore how inflammation impacts the efficacy and outcomes of cancer immunotherapies.

Main Methods:

• Literature review of studies on chronic inflammation and cancer.
• Analysis of the role of blood cells and proteins in cancer-associated inflammation.
• Examination of immune checkpoint inhibitors (CTLA-4, PD-1) and their interaction with inflammation.
• Review of prognostic and predictive value of inflammatory markers in immunotherapy.

Main Results:

• Inflammatory markers (neutrophils, lymphocytes, platelets, CRP, IL-6) are linked to cancer progression and prognosis.
• Immune checkpoints (CTLA-4, PD-1) are targets for immunotherapy, showing significant anti-tumor activity.
• Inflammation within the tumor microenvironment affects treatment response and patient outcomes.

Conclusions:

• Inflammatory markers hold prognostic and predictive value in cancer patients undergoing immunotherapy.
• Targeting immune checkpoints has revolutionized cancer treatment, with immunotherapy offering remarkable responses.
• Further research into the interplay between inflammation and immunotherapy is crucial for optimizing cancer care.